{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:26:09Z","timestamp":1789752369716,"version":"4.0.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Graft failure (GF) is a fatal complication of allogeneic stem cell transplantation, especially after haploidentical transplantation. The mortality of GF is nearly 100% without an effective salvage method. A second transplantation is usually necessary to save the patient's life. However, there is no standardized regimen, and the outcome is usually disappointing. We report on a prospective single-center study using a reduced-intensity conditioning regimen with different haploidentical donors (HIDs). Patients with GF after the first transplantation were enrolled in a prospective single-arm clinical trial (<jats:ext-link>ClinicalTrials.Gov<\/jats:ext-link> ID: NCT03717545) at the Peking University Institute of Hematology. The conditioning regimen consisted of fludarabine (30 mg\/m<jats:sup>2<\/jats:sup>) (days\u22126 to\u22122) and cyclophosphamide (1,000 mg\/m<jats:sup>2<\/jats:sup>\/day) (days\u22125 to\u22124). Patients underwent a second transplant from a different HID using a granulocyte colony-stimulating factor primed bone marrow and peripheral blood stem cells. The primary outcome was neutrophil engraftment at day 28. The secondary outcomes included platelet engraftment at day 100, transplant-related mortality (TRM) at day 30, TRM at day 100, and overall survival (OS) at 1 year. From March 2018 to June 2020, 13 patients were enrolled in this clinical trial. Of the 13 patients, five had acute myeloid leukemia, five had acute lymphoblastic leukemia, two had myelodysplastic syndromes, and one had a non-Hodgkin lymphoma. The median age at first transplantation was 38 years (range, 8\u201355 years). As for the first transplantation, 11 patients underwent haploidentical transplantations and two underwent unrelated donor transplantations. At the time of GF, three patients had complete donor chimerism, five had mixed chimerism, and five had complete recipient chimerism. The median time from the first transplantation to the second transplantation was 49 (range 35\u2013120) days. The medians of infused cell doses were as follows: mononuclear cells 7.93 (5.95\u201312.51) \u00d7 10<jats:sup>8<\/jats:sup>\/kg and CD34 + cells 2.28 (0.75\u20135.57) \u00d7 10<jats:sup>6<\/jats:sup>\/kg. All 13 patients achieved neutrophil engraftment after the second transplantation, with a median engraftment time of 11 (range 10\u201320) days after transplantation. The platelet engraftment rate on day 100 after transplantation was 76.9%. The TRMs at day 30, day 100, and 1-year were 0, 0, and 23.1%, respectively. The OS and disease-free survival at 1-year were 56.6 and 48.4%, respectively. For patients with GF after first transplantation, a second transplantation using a fludarabine\/cyclophosphamide regimen from a different HID was a promising salvage option. Further investigation is needed to confirm the suitability of this method.<\/jats:p>","DOI":"10.3389\/fmed.2021.604085","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T06:07:57Z","timestamp":1622786877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor"],"prefix":"10.3389","volume":"8","author":[{"given":"Yu-Qian","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/leu.2015.75","article-title":"Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"29","author":"Olsson","year":"2015","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplantation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2141.2000.02306.x","article-title":"Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia","volume":"111","author":"Guardiola","year":"2000","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3760\/cma.j.issn.0253-2727.2014.08.001","article-title":"[Second transplantation for 22 patients with graft failure after first allogeneic stem cell transplantation]","volume":"35","author":"Sun","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3109\/10428194.2014.930849","article-title":"Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients","volume":"56","author":"Ferra","year":"2015","journal-title":"Leukemia Lymphoma."},{"key":"B9","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"B10","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Seminars Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s41409-020-0928-z","article-title":"Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody","volume":"55","author":"Chang","year":"2020","journal-title":"Bone Marrow Transplantation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/bmt.2011.84","article-title":"Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplantation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/imj.13979","article-title":"Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case series","volume":"48","author":"Kliman","year":"2018","journal-title":"Int Med J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.bbmt.2014.03.024","article-title":"T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation","volume":"20","author":"Moscardo","year":"2014","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/bmt.2014.250","article-title":"Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients","volume":"50","author":"Tang","year":"2015","journal-title":"Bone Marrow Transplantation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.bbmt.2019.05.013","article-title":"Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy","volume":"25","author":"Prata","year":"2019","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13043","article-title":"T cell replete-haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies","volume":"21","author":"Mochizuki","year":"2017","journal-title":"Pediatric Transplantation."},{"key":"B19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/bmt.2011.158","article-title":"Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation","volume":"47","author":"Kanda","year":"2012","journal-title":"Bone Marrow Transplantation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijrobp.2018.12.031","article-title":"Immunosuppressive total nodal irradiation-based reconditioning regimens after graft rejection or graft failure in pediatric patients treated with myeloablative allogeneic hematopoietic cell transplantation","volume":"104","author":"Wegener","year":"2019","journal-title":"Int J Radiation Oncol Biol Phys."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25917.","article-title":"Haploidentical transplants for patients with graft failure after the first allograft","author":"Kongtim","year":"2020","journal-title":"Am J Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/s41409-020-0821-9","article-title":"Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Harada","year":"2020","journal-title":"Bone Marrow Transplantation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.bmt.1701146","article-title":"Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation","volume":"21","author":"Grandage","year":"1998","journal-title":"Bone Marrow Transplantation."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.604085\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T06:08:03Z","timestamp":1622786883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.604085\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":23,"alternative-id":["10.3389\/fmed.2021.604085"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.604085","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"article-number":"604085"}}